FusionNeoAntigen Logo

Home

Download

Statistics

Examples

Help

Contact

Terms of Use

Center for Computational Systems Medicine
leaf

Fusion Gene and Fusion Protein Summary

leaf

Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)

leaf

Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)

leaf

Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)

leaf

Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)

leaf

Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)

leaf

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)

leaf

Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)

leaf

Potential target of CAR-T therapy development

leaf

Information on the samples that have these potential fusion neoantigens

leaf

Fusion Protein Targeting Drugs - (Manual Curation)

leaf

Fusion Protein Related diseases - (Manual Curation)

Fusion Protein:FZD6-EIF3E

Fusion Gene and Fusion Protein Summary

check button Fusion gene summary
Fusion partner gene informationFusion gene name: FZD6-EIF3E
FusionPDB ID: 31963
FusionGDB2.0 ID: 31963
HgeneTgene
Gene symbol

FZD6

EIF3E

Gene ID

8323

3646

Gene namefrizzled class receptor 6eukaryotic translation initiation factor 3 subunit E
SynonymsFZ-6|FZ6|HFZ6|NDNC1|NDNC10EIF3-P48|EIF3S6|INT6|eIF3-p46
Cytomap

8q22.3

8q23.1

Type of geneprotein-codingprotein-coding
Descriptionfrizzled-6frizzled 6, seven transmembrane spanning receptorfrizzled family receptor 6frizzled homolog 6seven transmembrane helix receptoreukaryotic translation initiation factor 3 subunit EeIF-3 p48eukaryotic translation initiation factor 3 subunit 6eukaryotic translation initiation factor 3 subunit E isoform 2 transcripteukaryotic translation initiation factor 3, subunit 6 (48kD)euka
Modification date2020032720200313
UniProtAcc

O60353

Main function of 5'-partner protein: FUNCTION: Receptor for Wnt proteins. Most of frizzled receptors are coupled to the beta-catenin canonical signaling pathway, which leads to the activation of disheveled proteins, inhibition of GSK-3 kinase, nuclear accumulation of beta-catenin and activation of Wnt target genes. A second signaling pathway involving PKC and calcium fluxes has been seen for some family members, but it is not yet clear if it represents a distinct pathway or if it can be integrated in the canonical pathway, as PKC seems to be required for Wnt-mediated inactivation of GSK-3 kinase. Both pathways seem to involve interactions with G-proteins. May be involved in transduction and intercellular transmission of polarity information during tissue morphogenesis and/or in differentiated tissues. Together with FZD3, is involved in the neural tube closure and plays a role in the regulation of the establishment of planar cell polarity (PCP), particularly in the orientation of asymmetric bundles of stereocilia on the apical faces of a subset of auditory and vestibular sensory cells located in the inner ear (By similarity). {ECO:0000250|UniProtKB:Q61089}.

P60228

Main function of 5'-partner protein: FUNCTION: Component of the eukaryotic translation initiation factor 3 (eIF-3) complex, which is required for several steps in the initiation of protein synthesis (PubMed:17581632, PubMed:25849773, PubMed:27462815). The eIF-3 complex associates with the 40S ribosome and facilitates the recruitment of eIF-1, eIF-1A, eIF-2:GTP:methionyl-tRNAi and eIF-5 to form the 43S pre-initiation complex (43S PIC). The eIF-3 complex stimulates mRNA recruitment to the 43S PIC and scanning of the mRNA for AUG recognition. The eIF-3 complex is also required for disassembly and recycling of post-termination ribosomal complexes and subsequently prevents premature joining of the 40S and 60S ribosomal subunits prior to initiation (PubMed:17581632). The eIF-3 complex specifically targets and initiates translation of a subset of mRNAs involved in cell proliferation, including cell cycling, differentiation and apoptosis, and uses different modes of RNA stem-loop binding to exert either translational activation or repression (PubMed:25849773). Required for nonsense-mediated mRNA decay (NMD); may act in conjunction with UPF2 to divert mRNAs from translation to the NMD pathway (PubMed:17468741). May interact with MCM7 and EPAS1 and regulate the proteasome-mediated degradation of these proteins (PubMed:17310990, PubMed:17324924). {ECO:0000255|HAMAP-Rule:MF_03004, ECO:0000269|PubMed:17310990, ECO:0000269|PubMed:17324924, ECO:0000269|PubMed:17468741, ECO:0000269|PubMed:17581632, ECO:0000269|PubMed:25849773, ECO:0000269|PubMed:27462815}.
Ensembl transtripts involved in fusion geneENST idsENST00000358755, ENST00000522566, 
ENST00000523739, ENST00000540287, 
ENST00000519030, ENST00000519517, 
ENST00000220849, 
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)* DoF score8 X 4 X 6=19221 X 12 X 10=2520
# samples 821
** MAII scorelog2(8/192*10)=-1.26303440583379
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
log2(21/2520*10)=-3.58496250072116
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
Fusion gene context

PubMed: FZD6 [Title/Abstract] AND EIF3E [Title/Abstract] AND fusion [Title/Abstract]

Fusion neoantigen context

PubMed: FZD6 [Title/Abstract] AND EIF3E [Title/Abstract] AND neoantigen [Title/Abstract]

Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)FZD6(104312512)-EIF3E(109254142), # samples:2
Anticipated loss of major functional domain due to fusion event.FZD6-EIF3E seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
FZD6-EIF3E seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
FZD6-EIF3E seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
FZD6-EIF3E seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
FZD6-EIF3E seems lost the major protein functional domain in Hgene partner, which is a IUPHAR drug target due to the frame-shifted ORF.
FZD6-EIF3E seems lost the major protein functional domain in Tgene partner, which is a cell metabolism gene due to the frame-shifted ORF.
FZD6-EIF3E seems lost the major protein functional domain in Tgene partner, which is a CGC due to the frame-shifted ORF.
FZD6-EIF3E seems lost the major protein functional domain in Tgene partner, which is a essential gene due to the frame-shifted ORF.
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

check button Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez
PartnerGeneGO IDGO termPubMed ID
HgeneFZD6

GO:0035567

non-canonical Wnt signaling pathway

14747478

HgeneFZD6

GO:0043433

negative regulation of DNA-binding transcription factor activity

14747478

TgeneEIF3E

GO:0006413

translational initiation

17581632



check button Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr8:104312512/chr8:109254142)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.
FGviewer

check buttonRetention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

check buttonFusion gene breakpoints across FZD6 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure

check buttonFusion gene breakpoints across EIF3E (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure


Top

Fusion Amino Acid Sequences


check buttonFusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandSeq length
(transcript)
BP loci
(transcript)
Predicted start
(transcript)
Predicted stop
(transcript)
Seq length
(amino acids)
ENST00000522566FZD6chr8104312512+ENST00000220849EIF3Echr8109254142-18574672811714477
ENST00000358755FZD6chr8104312512+ENST00000220849EIF3Echr8109254142-18844943081741477
ENST00000523739FZD6chr8104312512+ENST00000220849EIF3Echr8109254142-17353452641592442

check buttonDeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandNo-coding scoreCoding score
ENST00000522566ENST00000220849FZD6chr8104312512+EIF3Echr8109254142-0.0002092550.9997907
ENST00000358755ENST00000220849FZD6chr8104312512+EIF3Echr8109254142-0.0002748420.99972516
ENST00000523739ENST00000220849FZD6chr8104312512+EIF3Echr8109254142-0.0003495440.9996505

check button Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for FZD6-EIF3E

check button +/-13 AA sequence from the breakpoints of the fusion protein sequences.
HgeneHchrHbpTgeneTchrTbpLength(fusion protein)BP in fusion proteinPeptide
FZD6chr8104312512EIF3Echr810925414234527GHYDQSIAAVEMEIYNEKELLQGKLD
FZD6chr8104312512EIF3Echr810925414246762GHYDQSIAAVEMEIYNEKELLQGKLD
FZD6chr8104312512EIF3Echr810925414249462GHYDQSIAAVEMEIYNEKELLQGKLD

Top

Potential FusionNeoAntigen Information of FZD6-EIF3E in HLA I

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
FZD6-EIF3E_104312512_109254142.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)
Fusion geneHchrHbpTgeneTchrTbpHLA IFusionNeoAntigen peptideBinding scoreImmunogenic scoreNeoantigen start (at BP 13)Neoantigen end (at BP 13)
FZD6-EIF3Echr8104312512chr8109254142494HLA-B51:01IAAVEMEI0.99920.5566614
FZD6-EIF3Echr8104312512chr8109254142494HLA-B35:08IAAVEMEIY0.99780.6873615
FZD6-EIF3Echr8104312512chr8109254142494HLA-B35:01IAAVEMEIY0.99580.8166615
FZD6-EIF3Echr8104312512chr8109254142494HLA-B47:01MEIYNEKEL0.99480.55491120
FZD6-EIF3Echr8104312512chr8109254142494HLA-B44:03MEIYNEKEL0.99280.95561120
FZD6-EIF3Echr8104312512chr8109254142494HLA-B18:01MEIYNEKEL0.96130.9111120
FZD6-EIF3Echr8104312512chr8109254142494HLA-B47:01VEMEIYNEK0.78050.5134918
FZD6-EIF3Echr8104312512chr8109254142494HLA-B39:13MEIYNEKEL0.56380.85841120
FZD6-EIF3Echr8104312512chr8109254142494HLA-B13:02SIAAVEMEI0.41820.5343514
FZD6-EIF3Echr8104312512chr8109254142494HLA-B39:08MEIYNEKEL0.67460.72741120
FZD6-EIF3Echr8104312512chr8109254142494HLA-B51:14IAAVEMEI0.99920.5611614
FZD6-EIF3Echr8104312512chr8109254142494HLA-B40:04MEIYNEKEL0.99920.62641120
FZD6-EIF3Echr8104312512chr8109254142494HLA-B35:77IAAVEMEIY0.99580.8166615
FZD6-EIF3Echr8104312512chr8109254142494HLA-B35:11IAAVEMEIY0.99550.8475615
FZD6-EIF3Echr8104312512chr8109254142494HLA-B35:23IAAVEMEIY0.99550.8218615
FZD6-EIF3Echr8104312512chr8109254142494HLA-B35:20IAAVEMEIY0.99530.8516615
FZD6-EIF3Echr8104312512chr8109254142494HLA-B44:07MEIYNEKEL0.99280.95561120
FZD6-EIF3Echr8104312512chr8109254142494HLA-B44:26MEIYNEKEL0.99280.95561120
FZD6-EIF3Echr8104312512chr8109254142494HLA-B44:13MEIYNEKEL0.99280.95561120
FZD6-EIF3Echr8104312512chr8109254142494HLA-A69:01SIAAVEMEI0.98550.5584514
FZD6-EIF3Echr8104312512chr8109254142494HLA-C03:02IAAVEMEIY0.98150.968615
FZD6-EIF3Echr8104312512chr8109254142494HLA-B35:43IAAVEMEIY0.97940.8178615
FZD6-EIF3Echr8104312512chr8109254142494HLA-A68:02EIYNEKELL0.9780.52751221
FZD6-EIF3Echr8104312512chr8109254142494HLA-B35:30IAAVEMEIY0.96810.6456615
FZD6-EIF3Echr8104312512chr8109254142494HLA-B35:17IAAVEMEIY0.96810.6456615
FZD6-EIF3Echr8104312512chr8109254142494HLA-B35:24IAAVEMEIY0.96570.9015615
FZD6-EIF3Echr8104312512chr8109254142494HLA-B18:08MEIYNEKEL0.96160.81751120
FZD6-EIF3Echr8104312512chr8109254142494HLA-B18:05MEIYNEKEL0.96130.9111120
FZD6-EIF3Echr8104312512chr8109254142494HLA-B18:06MEIYNEKEL0.95330.91581120
FZD6-EIF3Echr8104312512chr8109254142494HLA-B18:11MEIYNEKEL0.9520.88981120
FZD6-EIF3Echr8104312512chr8109254142494HLA-B18:06VEMEIYNEK0.9260.8757918
FZD6-EIF3Echr8104312512chr8109254142494HLA-A69:01EIYNEKELL0.90950.6091221
FZD6-EIF3Echr8104312512chr8109254142494HLA-B18:03MEIYNEKEL0.90740.90231120
FZD6-EIF3Echr8104312512chr8109254142494HLA-B41:03MEIYNEKEL0.79520.61741120
FZD6-EIF3Echr8104312512chr8109254142494HLA-C12:02IAAVEMEIY0.76010.9723615
FZD6-EIF3Echr8104312512chr8109254142494HLA-B39:11MEIYNEKEL0.67610.751120
FZD6-EIF3Echr8104312512chr8109254142494HLA-B39:02MEIYNEKEL0.61190.86591120
FZD6-EIF3Echr8104312512chr8109254142494HLA-C16:04IAAVEMEIY0.60860.9833615
FZD6-EIF3Echr8104312512chr8109254142494HLA-C16:01IAAVEMEIY0.33980.964615
FZD6-EIF3Echr8104312512chr8109254142494HLA-C02:10IAAVEMEIY0.02550.9721615
FZD6-EIF3Echr8104312512chr8109254142494HLA-C02:02IAAVEMEIY0.02550.9721615
FZD6-EIF3Echr8104312512chr8109254142494HLA-B40:04MEIYNEKELL0.99160.59081121
FZD6-EIF3Echr8104312512chr8109254142494HLA-B40:04VEMEIYNEKEL0.99980.6779920
FZD6-EIF3Echr8104312512chr8109254142494HLA-B41:03VEMEIYNEKEL0.99280.6423920

Top

Potential FusionNeoAntigen Information of FZD6-EIF3E in HLA II

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
FZD6-EIF3E_104312512_109254142.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).
Fusion geneHchrHbpTgeneTchrTbpHLA IIFusionNeoAntigen peptideNeoantigen start (at BP 13)Neoantigen end (at BP 13)
FZD6-EIF3Echr8104312512chr8109254142494DRB1-1201DQSIAAVEMEIYNEK318
FZD6-EIF3Echr8104312512chr8109254142494DRB1-1203DQSIAAVEMEIYNEK318
FZD6-EIF3Echr8104312512chr8109254142494DRB1-1205DQSIAAVEMEIYNEK318
FZD6-EIF3Echr8104312512chr8109254142494DRB1-1206DQSIAAVEMEIYNEK318
FZD6-EIF3Echr8104312512chr8109254142494DRB1-1207DQSIAAVEMEIYNEK318
FZD6-EIF3Echr8104312512chr8109254142494DRB1-1208DQSIAAVEMEIYNEK318
FZD6-EIF3Echr8104312512chr8109254142494DRB1-1210DQSIAAVEMEIYNEK318
FZD6-EIF3Echr8104312512chr8109254142494DRB1-1211DQSIAAVEMEIYNEK318
FZD6-EIF3Echr8104312512chr8109254142494DRB1-1212DQSIAAVEMEIYNEK318
FZD6-EIF3Echr8104312512chr8109254142494DRB1-1213DQSIAAVEMEIYNEK318
FZD6-EIF3Echr8104312512chr8109254142494DRB1-1214DQSIAAVEMEIYNEK318
FZD6-EIF3Echr8104312512chr8109254142494DRB1-1215DQSIAAVEMEIYNEK318
FZD6-EIF3Echr8104312512chr8109254142494DRB1-1217DQSIAAVEMEIYNEK318
FZD6-EIF3Echr8104312512chr8109254142494DRB1-1218DQSIAAVEMEIYNEK318
FZD6-EIF3Echr8104312512chr8109254142494DRB1-1219DQSIAAVEMEIYNEK318
FZD6-EIF3Echr8104312512chr8109254142494DRB1-1221DQSIAAVEMEIYNEK318
FZD6-EIF3Echr8104312512chr8109254142494DRB1-1223DQSIAAVEMEIYNEK318
FZD6-EIF3Echr8104312512chr8109254142494DRB1-1503AVEMEIYNEKELLQG823
FZD6-EIF3Echr8104312512chr8109254142494DRB1-1503AAVEMEIYNEKELLQ722
FZD6-EIF3Echr8104312512chr8109254142494DRB1-1503VEMEIYNEKELLQGK924
FZD6-EIF3Echr8104312512chr8109254142494DRB1-1503IAAVEMEIYNEKELL621
FZD6-EIF3Echr8104312512chr8109254142494DRB1-1510AVEMEIYNEKELLQG823
FZD6-EIF3Echr8104312512chr8109254142494DRB1-1512AVEMEIYNEKELLQG823
FZD6-EIF3Echr8104312512chr8109254142494DRB1-1523AVEMEIYNEKELLQG823
FZD6-EIF3Echr8104312512chr8109254142494DRB1-1523AAVEMEIYNEKELLQ722
FZD6-EIF3Echr8104312512chr8109254142494DRB1-1523VEMEIYNEKELLQGK924

Top

Fusion breakpoint peptide structures of FZD6-EIF3E

check button3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.
File nameBPseqHgeneTgeneHchrHbpTchrTbpAAlen
3570IAAVEMEIYNEKELFZD6EIF3Echr8104312512chr8109254142494

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of FZD6-EIF3E

check buttonVirtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.
HLA allelePDB IDFile nameBPseqDocking scoreGlide score
HLA-B14:023BVN3570IAAVEMEIYNEKEL-7.15543-7.26883
HLA-B14:023BVN3570IAAVEMEIYNEKEL-4.77435-5.80965
HLA-B52:013W393570IAAVEMEIYNEKEL-6.80875-6.92215
HLA-B52:013W393570IAAVEMEIYNEKEL-4.20386-5.23916
HLA-A11:014UQ23570IAAVEMEIYNEKEL-7.5194-8.5547
HLA-A11:014UQ23570IAAVEMEIYNEKEL-6.9601-7.0735
HLA-A24:025HGA3570IAAVEMEIYNEKEL-7.52403-7.63743
HLA-A24:025HGA3570IAAVEMEIYNEKEL-5.82433-6.85963
HLA-B27:056PYJ3570IAAVEMEIYNEKEL-3.28285-4.31815
HLA-B44:053DX83570IAAVEMEIYNEKEL-5.91172-6.94702
HLA-B44:053DX83570IAAVEMEIYNEKEL-4.24346-4.35686

Top

Vaccine Design for the FusionNeoAntigens of FZD6-EIF3E

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptide sequenceFusionNeoAntigen RNA sequence
FZD6-EIF3Echr8104312512chr81092541421120MEIYNEKELATGGAGATATATAATGAAAAGGAATTA
FZD6-EIF3Echr8104312512chr81092541421121MEIYNEKELLATGGAGATATATAATGAAAAGGAATTATTA
FZD6-EIF3Echr8104312512chr81092541421221EIYNEKELLGAGATATATAATGAAAAGGAATTATTA
FZD6-EIF3Echr8104312512chr8109254142514SIAAVEMEIAGTATTGCCGCGGTGGAAATGGAGATA
FZD6-EIF3Echr8104312512chr8109254142614IAAVEMEIATTGCCGCGGTGGAAATGGAGATA
FZD6-EIF3Echr8104312512chr8109254142615IAAVEMEIYATTGCCGCGGTGGAAATGGAGATATAT
FZD6-EIF3Echr8104312512chr8109254142918VEMEIYNEKGTGGAAATGGAGATATATAATGAAAAG
FZD6-EIF3Echr8104312512chr8109254142920VEMEIYNEKELGTGGAAATGGAGATATATAATGAAAAGGAATTA

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptideFusionNEoAntigen RNA sequence
FZD6-EIF3Echr8104312512chr8109254142318DQSIAAVEMEIYNEKGACCAGAGTATTGCCGCGGTGGAAATGGAGATATATAATGAAAAG
FZD6-EIF3Echr8104312512chr8109254142621IAAVEMEIYNEKELLATTGCCGCGGTGGAAATGGAGATATATAATGAAAAGGAATTATTA
FZD6-EIF3Echr8104312512chr8109254142722AAVEMEIYNEKELLQGCCGCGGTGGAAATGGAGATATATAATGAAAAGGAATTATTACAA
FZD6-EIF3Echr8104312512chr8109254142823AVEMEIYNEKELLQGGCGGTGGAAATGGAGATATATAATGAAAAGGAATTATTACAAGGT
FZD6-EIF3Echr8104312512chr8109254142924VEMEIYNEKELLQGKGTGGAAATGGAGATATATAATGAAAAGGAATTATTACAAGGTAAA

Top

Information of the samples that have these potential fusion neoantigens of FZD6-EIF3E

check button These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.
Cancer typeFusion geneHchrHbpHenstTchrTbpTenstSample
ESCAFZD6-EIF3Echr8104312512ENST00000358755chr8109254142ENST00000220849TCGA-LN-A4A6

Top

Potential target of CAR-T therapy development for FZD6-EIF3E

check button Predicted 3D structure. We used RoseTTAFold.

check buttonRetention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features


* Minus value of BPloci means that the break point is located before the CDS.
- In-frame and retained 'Transmembrane'.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note

check button Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.
HgeneHchrHbpHenstTgeneTchrTbpTenstDeepLoc result

Top

Related Drugs to FZD6-EIF3E

check button Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDrugSourcePMID

Top

Related Diseases to FZD6-EIF3E

check button Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDiseaseSourcePMID

check button Diseases associated with fusion partners.
(DisGeNet 4.0)
PartnerGeneDisease IDDisease name# pubmedsSource